Raiffeisen Bank International AG Sells 18,503 Shares of AbbVie Inc. $ABBV

Raiffeisen Bank International AG lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 5.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 320,903 shares of the company’s stock after selling 18,503 shares during the quarter. AbbVie accounts for approximately 0.9% of Raiffeisen Bank International AG’s portfolio, making the stock its 27th biggest position. Raiffeisen Bank International AG’s holdings in AbbVie were worth $59,492,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ABBV. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the 2nd quarter valued at about $25,000. TD Capital Management LLC grew its stake in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie during the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the second quarter valued at about $36,000. Finally, Bear Mountain Capital Inc. boosted its stake in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $232.43 on Monday. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The business has a 50-day simple moving average of $224.89 and a two-hundred day simple moving average of $204.04. The firm has a market cap of $410.79 billion, a price-to-earnings ratio of 110.68, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ABBV shares. Piper Sandler reiterated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. HSBC set a $225.00 price objective on shares of AbbVie in a report on Thursday, October 2nd. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price for the company in a research note on Thursday, August 7th. Bank of America boosted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Wells Fargo & Company upped their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.